Mod­er­na CEO Stéphane Ban­cel out­lines a prospec­tive moth­er­lode of Covid-19 vac­cine rev­enue — will a back­lash fol­low?

Mod­er­na shows no sign of slow­ing down, or turn­ing char­i­ta­ble when it comes to pric­ing sup­plies of its Covid-19 vac­cine.

One of the lead­ers in the Phase III race to get a Covid-19 vac­cine across the fin­ish line in record time, Mod­er­na says it’s on track to com­plete en­roll­ment in one of the most avid­ly watched stud­ies in the world next month. And the biotech has al­ready banked some $400 mil­lion in de­posits for vac­cine sup­ply as it works through ne­go­ti­a­tions with coun­tries around the world — as CEO Stéphane Ban­cel sets out to hire a com­mer­cial team.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN